MedSci Healthcare Holdings Limited 梅斯健康控股有限公 司 ANNUAL REPORT 2024 股份代號 : 2415 （於開曼群島註冊成立之有限公司） 年報 2024 (Incorporated in the Cayman Islands with limited liability) MedSci Healthcare Holdings Limited 梅斯健康控股有限公 司 Stock code : 2415 ANNUAL REPORT 2024 MedSci Healthcare Holdings Limited 梅斯健康控股有限公 司 年報 目錄 | 公司資料 | 2 | | --- | --- | | 主席報告 | 4 | | 財務概要 | 6 | | 財務摘要 | 7 | | 管理層討論及分析 | 8 | | 企業管治報告 | 22 | | 董事會報告 | 36 | | 董事及高級管理層 | 68 | | 獨立核數師報告 | 74 | | 綜合損益及其他全面收益表 | 79 | | 綜合財務狀況表 | 81 | | 綜合權益變動表 | 83 | | 綜合現金流 ...

MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 截至2024年12月31日止年度之 年度業績公告 梅斯健康控股有限公司董事會現公佈本公司及其附屬公司截至2024年12月31日止年度經 審核綜合年度業績，連同截至2023年12月31日止年度的比較數字。 – 1 – | 財務摘要 | | | | | | | --- | --- | --- | --- | --- | --- | | | | | 截至12月31日止年度 | | 同比變動* | | | | 2024年 | | 2023年 | | | | | | （人民幣千元） | | % | | 收益 | | 260,623 | | 349,194 | –25.4 | | 銷售成本 | | 98,449 | | 132,587 | –25.7 | | 毛利 | ...

MedSci Healthcare Holdings Limited MedSci Healthcare Holdings Limited 梅斯健康控股有限公 司 (Incorporated in the Cayman Islands with limited liability) Stock code : 2415 梅斯健康控股有限公司 INTERIM REPORT INTERIM REPORT 2024 中期報告 MedSci Healthcare Holdings Limited | --- | --- | --- | |---------------------------------------------------------------------------|-------|-------| | | | | | 梅斯健康控股有限公 司 （ 於開曼群島註冊成立之有限公司） 股份代號： 2415 | | | | | | | 目錄 | --- | --- | |--------------------------|-------| | | | | | | | 公司資料 | 2 | | 業務概覽 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 截至2024年6月30日止六個月之中期業績公告 梅斯健康控股有限公司（「本公司」或「我們」）董事（「董事」）會（「董事會」）現公佈本公司及 其附屬公司（統稱「本集團」）截至2024年6月30日止六個月（「報告期間」）未經審核綜合中 期業績，連同截至2023年6月30日止六個月（「相應期間」）的比較數字。 – 1 – 財務摘要 | --- | --- | --- | --- | --- | --- | |----------------------------------------------|--------------|--------------|---------------------------------------------------- ...

• 倘我們的任何綜合聯屬實體宣佈破產或面臨解散或清盤程序，則我們可能會喪失使用我們綜合聯屬實體 所持牌照、批文及資產的能力或無法以其他方式從中受益。 有關與合約安排有關的風險詳情，請參閱招股章程「風險因素 — 與合約安排有關的風險」一節。 51 梅斯健康控股有限公司 2023年報 董事會報告 上市規則的涵義及聯交所豁免 獨立非執行董事已審閱合約安排，並確認： (iii) 合約安排就本集團而言屬公平合理或有利，且符合股東的整體利益。 根據上市規則第14A.55條，獨立非執行董事已審閱合約安排項下擬進行構成本公司持續關連交易的交易，並確 認該等持續關連交易(i)於本集團日常及一般業務過程中訂立；(ii)按一般商業條款或更佳條款訂立；及(iii)根據監 管交易的相關協議按公平合理，且符合本公司及股東整體利益的條款訂立。 於截至2023年12月31日止年度期間，並無向董事或五位最高薪酬人員（如本年報的綜合財務報表附註9中載列） 支付任何金額，作為加入本集團或加入本集團時獎勵或作為離職補償。除本年報財務報表附註8所披露外，於 截至2023年12月31日止年度期間，並無支付任何董事袍金予董事。 董事及最高行政人員於本公司 ...

權益 母公司擁有人應佔權益 | --- | --- | --- | --- | |--------------|-------|-----------|-----------| | | | | | | 已發行資本 | 11 | 420 | 5 | | 庫存股份 | | (42,037) | —* | | 可轉換優先股 | | — | 53,417 | | 儲備 | | 1,161,996 | (195,686) | 權益總額╱（資產虧絀） 1,120,379 (142,264) * 金額低於人民幣1,000元。 – 12 – 綜合財務資料的主要附註 1. 公司及集團資料 梅斯健康控股有限公司（「本公司」）於2021年6月22日於開曼群島根據開曼群島法例註冊成立為獲豁免 有限公司。本公司的註冊辦事處地址為89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands。 本公司為一間投資控股公司。於截至2023年12月31日止年度內，本公司及其附屬公司（統稱為「本集 團」）的主要業務為於中華人民共和國（「中國」）提供醫師平台解決方案、精準全渠道營銷 ...

User Base and Market Position - As of June 30, 2023, MedSci Healthcare Holdings Limited has approximately 3.0 million registered physician users on its platform, with an average of about 2.8 million monthly active users[6]. - The platform has a high proportion of senior physician users, with 72% of registered physicians holding the title of Associate Chief Physician or above, according to the National Health Commission of China[6]. - The company served 180 pharmaceutical enterprises with its precision omnichannel marketing and RWS services, covering 336 pharmaceutical-related products[103]. - The doctor platform business continues to show stable growth, providing comprehensive support for medical professionals[104]. - The company plans to strengthen its leading position in the doctor platform through internal innovation and external acquisitions in the second half of 2023[108]. - The company aims to create specialized platforms for different medical fields to enhance user experience and value[107]. Financial Performance - Total revenue for the period reached RMB 151,400,000, with contributions from physician platform solutions (RMB 43,876,000), precision omnichannel marketing solutions (RMB 85,523,000), and real-world research solutions (RMB 22,001,000)[44]. - The company’s financial position shows a significant recovery with total comprehensive income of RMB 54,456 thousand for the period[34]. - The company’s revenue increased by approximately 11.9% from RMB 135.3 million in the six months ended June 30, 2022, to RMB 151.4 million in the same period of 2023[127]. - Gross profit for the six months ended June 30, 2023, was approximately RMB 88.3 million, an increase of about 8.2% compared to RMB 81.6 million for the same period in 2022[127]. - The net profit for the six months ended June 30, 2023, was approximately RMB 11.9 million, a significant recovery from a net loss of approximately RMB 107.2 million in the same period of 2022[127]. - The adjusted net profit for the six months ended June 30, 2023, was approximately RMB 12.2 million, an increase of about 15.5% compared to RMB 10.6 million for the same period in 2022[127]. Assets and Liabilities - As of June 30, 2023, the company reported a net asset value of RMB 1,129,082 thousand, compared to a net liability of RMB (142,264) thousand as of December 31, 2022[32]. - The total non-current liabilities decreased to RMB 2,345 thousand from RMB 724,975 thousand, primarily due to the absence of convertible redeemable preferred shares[32]. - The total assets as of June 30, 2023, were reported at RMB 29,786,000, compared to RMB 37,720,000 as of December 31, 2022[65]. - The company had no bank borrowings or interest-bearing debts, with lease liabilities totaling approximately RMB 7.6 million[148]. - The company had no significant capital commitments as of June 30, 2023[170]. - The company has no significant contingent liabilities as of June 30, 2023[191]. Shareholder and Equity Information - Major shareholders include Microhealth Limited with a 29.30% stake and Dtx Health Limited with a 23.32% stake as of June 30, 2023[24]. - The company’s equity attributable to owners increased significantly, with reserves rising to RMB 1,128,692 thousand from RMB (195,686) thousand[32]. - The total issued share capital as of June 30, 2023, was RMB 420 thousand, reflecting an increase from previous periods[34]. - The company has implemented an employee equity incentive plan, with economic benefits capped at 20% of the relevant shares awarded annually[21]. - The new equity incentive plan ("New Plan") was effective from April 20, 2022, replacing the previous 2021 plan, with Meiyue Limited and Meilong Limited holding 41,848,900 shares and 24,216,550 shares respectively as of April 27, 2023[73]. Research and Development - Research and development expenses for the period included direct employee costs and recurring costs, reflecting the group's commitment to innovation[48]. - Research and development expenses increased by approximately 83.8% from RMB 10.4 million for the six months ended June 30, 2022, to RMB 19.1 million in the same period of 2023, due to a large-scale R&D project initiated in mid-2022[119]. - The company plans to launch its proprietary AI program, MSchat, in the second half of 2023, following internal testing in the first half of 2023[125]. Compliance and Governance - The board confirmed compliance with all applicable corporate governance code provisions since the listing date until June 30, 2023[195]. - The company has no plans to purchase, sell, or redeem any of its listed securities from the listing date until June 30, 2023[197]. - The board can amend, suspend, or terminate the equity incentive plan as per the plan rules[187]. Taxation and Financial Reporting - The effective tax rate for the group’s subsidiaries in mainland China is set at 25%, except for Shanghai Meis Medical, which benefits from a reduced rate of 15% due to its "High-tech Enterprise" status[49]. - The income tax expense increased from approximately RMB -0.2 million for the six months ended June 30, 2022, to approximately RMB 1.0 million for the same period in 2023, mainly due to a decrease in listing-related expenses[161]. - The group implemented the revised International Financial Reporting Standards (IFRS) 17 and IFRS 9 starting January 1, 2023, with no impact on the interim condensed consolidated financial information[40].

MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） – 1 – * 同比變動%指報告期間與相應期間的比較。 | --- | --- | --- | --- | --- | --- | |------------------------|--------------|--------------|------------------------|-------|------------| | | 2023 年 | 截至 6 月 30 | 日止六個月 \n2022 年 | | 同比變動 * | | | （未經審核） | | （未經審核） | | | | | | （人民幣千元 | , 百分比除外） | | | | | 人民幣 | % | 人民幣 | % | % | | 收益 | | | | | | | 精準全渠道營銷解決方案 | 85,523 | 56.5 | 76,437 | 56.5 | 11.9 | | 醫師平台解決方案 | 43,876 | 29.0 | 36,985 | 27.3 | 18.6 | | RWS ...